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ABSTRACT  38 
 39 
Purpose: To evaluate the efficacy of electronic head-mounted Low Vision Aid (ehLVA) SightPlus 40 
(GiveVision, UK) and to determine which people with low vision would see themselves likely using an 41 
ehLVA like this. 42 
Methods: Sixty participants with Low Vision aged 18 to 93 used SightPlus during an in-clinic study 43 
session using a mixed methods design. Visual acuity (ETDRS), contrast sensitivity (Pelli Robson) and 44 
reading performance (MNREAD) were measured binocularly at baseline (no device), with the device 45 
in ‘normal’ mode (zoom only), and with preferred enhanced mode (zoom and one out of four digital 46 
image enhancements). At the end of the session, a short questionnaire recorded willingness to use 47 
an ehLVA like SightPlus, potential use cases, positive/negative comments and adverse effects. 48 
Results:  Binocular distance visual acuity improved significantly by 0.63 logMAR on average 49 
(p<0.0001) to 0.20 logMAR. Contrast sensitivity improved significantly by 0.22 log units (p<0.0001) to 50 
1.21 log units with zoom only and by 0.40 log units to 1.37 log units with zoom and preferred image 51 
enhancement. Reading performance improved significantly for near visual acuity and critical print 52 
size (p<0.015), however reading speed significantly decreased (p<0.0001). Nearly half (47%) of the 53 
participants indicated they would use an ehLVA like SightPlus, especially for television, reading and 54 
entertainment (e.g. theatre). Multivariate logistic regression showed that proportion of lifetime 55 
affected, baseline contrast sensitivity and use of electronic LVAs explained 41% of the variation in 56 
willingness to use. 57 
Conclusions:  SightPlus improves visual function in people with low vision and would be used in its 58 
current form by half of the people who tried it. Adverse effects were rare and resolved when the 59 
device was removed. Future work should focus on comparing ehLVAs through repeatable real-world 60 
tasks and impact on quality of life. 61 
  62 
 
Introduction 63 
Electronic head-mounted Low Vision Aids (ehLVAs) have experienced a technological step change 64 
over the last decade.1 2  A 2017 review of head-mounted displays for people with low vision 65 
highlighted the advantages of such technology over conventional desk-mounted or handheld sight 66 
aids.3 Since early commercial devices such as the Low Vision Enhancement System were first 67 
produced in the 1990s,4 advances in consumer technology have led to the availability of smaller, 68 
lighter, more versatile ehLVAs, including SightPlus (GiveVision, Birmingham, UK), eSight (eSight 69 
Corporation, Toronto, ON, Canada), IrisVision (IrisVision Global, Pleasanton, CA, USA), OxSight 70 
(OxSight Ltd, Oxford, UK) the new JORDY (Enhanced Vision Services, Huntington Beach, CA, USA), 71 
with several other devices being developed. 5-8 SightPlus is a commercially available ehLVA and 72 
registered as a Class I medical device. It is designed around a smartphone (serving as a camera, 73 
image processor and display) inserted into a virtual reality (VR) headset serving as the optical 74 
system. To date, clinical evidence for the efficacy of VR-and-smartphone-based ehLVAs such as 75 
SightPlus is lacking. 76 
 77 
Modern ehLVAs can embed digital sight enhancement algorithms that have been proven effective in 78 
laboratory settings for decades.9-16 A 2015 review of 37 research papers highlighted the benefit of 79 
various image processing techniques for the visually impaired, albeit with inconsistent preferences 80 
between people.1 A more recent review of ehLVAs illustrated existing strategies to sight 81 
enhancement and showed improvements in contrast sensitivity.2 However, to date, only two studies 82 
have been published demonstrating efficacy of wearables across substantial patient numbers: one 83 
for the eSight ehLVA device,17 and one for Orcam, a spectacle mounted text-to-speech system.18 The 84 
eSight study showed improvements in visual acuity, contrast sensitivity, reading performance and 85 
functional vision in a self-selected group of 51 adults who had demonstrated motivation to wear the 86 
device. Data are lacking for people unaware of ehLVAs or for a more general population of people 87 
with visual impairment. 88 
 
 89 
In this study, we evaluated the performance of SightPlus (GiveVision, Birmingham, UK; Figure 1).  90 
This device was chosen as it was commercially available in the United Kingdom, was relatively 91 
affordable, and there were anecdotal reports of significant visual benefits associated with this 92 
device.  We hypothesised that acuity, contrast sensitivity and reading speed would improve similarly 93 
to a different ehLVA using different technology (eSight).  We anticipated that poorer baseline acuity 94 
and familiarity with electronic low vision aids would predict willingness to use the device. 95 
 96 
 97 




Figure 2.  Text and a pictorial scene as displayed through five different modes offered by SightPlus.  101 
a. Reference image; b. Normal mode, c. Enhanced mode, d. Contrast mode, e. Inverted mode, f. Text 102 
mode. 103 
 104 
Materials and Methods 105 
 106 
Ethics 107 
Ethical approval for the study was obtained from the Health Research Authority (IRAS number 108 
237229), and local approval was obtained from the North Thames Clinical Research Network.  109 
Participants gave written informed consent after the purpose of the study was explained and prior 110 




Sixty participants were recruited from low vision and medical retina clinics at Moorfields Eye 114 
Hospital. This clinic is in a tertiary centre with a relatively high proportion of younger patients with 115 
inherited retinal disease.19 All participants met the definition of visual impairment suggested by Leat: 116 
having best monocular or binocular visual acuity of worse than 6/7.5, horizontal visual field of less 117 
than 146 degrees to Goldmann III4e targets, or contrast sensitivity worse than 1.5 log units.20 All 118 
were over 18 years of age, fluent in written and spoken English and able to hear and understand 119 
instructions whilst wearing the device. 120 
 121 
Materials 122 
SightPlus offers proprietary sight enhancement software through a smartphone (S8, Samsung, South 123 
Korea) mounted in a virtual reality headset (Prime, Homido, France), controlled through a handheld 124 
Bluetooth remote control. The device weighs 465g. The smartphone has a total screen resolution of 125 
2960 x 1440 pixels (approximately half width used per eye) and presents a digital image on an 126 
AMOLED screen. The headset’s lenses provide an approximately 110 degree diagonal (80 degree 127 
horizontal) field of view, while the software offers approximately 0.7x to 24.3x magnification (38x 128 
relative zoom). Brightness, exposure, blue light filter and inter-pupillary distance are customisable. 129 
SightPlus has five image enhancement modes (Figure 2), each of which modifies the whole image: 130 
‘Normal mode’ shows a full colour video feed. ‘Enhanced mode’ enables subtle feature 131 
enhancement by modulating selected spatial frequency components, resulting in sharper edges and 132 
smoother colours. ‘Contrast mode’ offers strong edge enhancement. ‘Inverted mode’ displays an 133 
inverted greyscale image, rendering white as black and vice versa. ‘Text mode’ offers a binary image 134 





Data collection was performed following a low vision assessment conducted as part of a routine low 139 
vision clinic assessment by the first author. As part of this initial assessment, baseline visual acuity 140 
was measured binocularly with best refractive correction on a retro illuminated distance logMAR 141 
chart (Lighthouse Series ETDRS chart, Precision Vision, Woodstock, IL, USA).  Letter-by-letter scoring 142 
was used and participants were encouraged to guess until no letters were correctly identified on a 143 
line.  Where no letters were read at 4m, the chart was moved to 2 metres, 1 metre, and 50cm.  If no 144 
letters were identified from 50cm, hand movements and perception of light was used. Contrast 145 
sensitivity was measured using a Pelli-Robson chart at 1 metre (Precision Vision, Woodstock, IL, USA) 146 
with the triplet being scored as read correctly when two of three letters were read.  Reading 147 
performance (near visual acuity, critical print size, reading speed) was measured using the iPad 148 
version of the MNREAD test (Regents of the University of Minnesota, Minneapolis, MN, USA).21 149 
Visual field data were extracted from the participant’s medical records.  Those with loss only within 150 
the central 15 degrees were classified as having central loss, those with loss only beyond 15 degrees 151 
as peripheral loss, those with loss in both regions as mixed, and without field loss as no field loss.   152 
 153 
During the study session, each participant wore SightPlus for approximately 10-15 minutes under 154 
the supervision of the first author.  Interpupillary distance of the device was adjusted optically and in 155 
software to ensure there was no diplopia and participants were allowed to become comfortable 156 
with its controls. All image enhancement modes were demonstrated.  Once the participant was 157 
comfortable with the device and its controls, visual acuity, contrast sensitivity and reading 158 
performance were then assessed with the device: first in normal mode, and subsequently in the 159 
preferred image enhancement mode. Free choice of enhancement mode was allowed to explore the 160 
best-case scenario achievable with SightPlus; time constraints did not allow a systematic assessment 161 
of all modes. Participants were able to use a freely chosen zoom level for a given task. Data 162 
collection was terminated if participants self-reported nausea or any other unpleasant effects 163 
preventing them from continuing the session or if they expressed the wish to withdraw. 164 
 
 165 
Statistical analysis: efficacy 166 
A repeated measures ANOVA was performed to compare between baseline, normal mode and 167 
preferred enhanced mode for distance visual acuity, contrast sensitivity and reading performance 168 
metrics (near visual acuity, critical print size and reading speed). In case of significance, pairwise 169 
post-hoc tests with Bonferroni correction were conducted. 170 
 171 
Statistical analysis: willingness to use device 172 
Willingness to use an ehLVA like SightPlus was assessed against the following 15 individual predictor 173 
variables through sub-group analysis: demographic factors (age, gender, work status (working, not 174 
working), current use of electronic magnifiers (yes, no)); disease factors (progressive or stable, time 175 
since diagnosis, percentage lifetime with sight loss); visual metrics (type of visual field loss (central, 176 
visual, peripheral, mixed, none) as well as baseline, difference and end point in normal mode for 177 
binocular visual acuity and binocular contrast sensitivity. For continuous variables, an independent t-178 
test was performed, with ‘would use’ as the grouping variable. For nominal data, a Х2 test was 179 
performed. Stepwise multivariate regression was performed using the same demographic, disease 180 
and visual factors. 181 
 182 
Qualitative analysis 183 
At the end of the session, a semi-structured questionnaire was administered, where each participant 184 
was asked four of the following five questions: 185 
1. ‘Would you be willing to use a device like this?’ 186 
2. (If response to question 1 is ‘yes’): ‘what would you use it for?’;  187 
3. (If reponse to question 1 is ‘no’): ‘why not?’ 188 
4. ‘What are the strengths of the device at present?’ 189 
5. ‘What are the weaknesses of the device at present?’ 190 
 
Participants were encouraged to answer each question as fully as possible.  Key points were written, 191 
and the investigator confirmed the responses with the participant.  A grounded theory approach was 192 
used for analysis, where responses were coded and grouped into categories. Categories of responses 193 
are reported. 194 
 195 
Adverse effects 196 
Participants were asked whether they experienced nausea, claustrophobia, headache, eyestrain, or 197 
any other adverse response. 198 
 199 
Results 200 
Mean (SD) participant age was 51.4 (18.7) years. 23 participants (38%) were female. Mean (SD) 201 
visual acuity with both eyes open was 0.82 (0.39) logMAR (6/40; 20/132) with a range of 0.04 202 
logMAR (6/7; 20/22) to hand movements.  Eight participants (13%) had no visual field loss, 27 (45%) 203 
had central field loss, 17 (28%) had peripheral field loss, and eight (13%) had both central and 204 
peripheral field loss.  205 
 206 
Eleven participants had retinitis pigmentosa or Usher syndrome, 11 had other inherited retinal 207 
diseases, 11 had inherited macular diseases, 6 had age-related macular disease, 6 had optic neuritis, 208 
3 had albinism, 2 had glaucoma, and 2 had diabetic eye disease.  One participant had each of optic 209 
atrophy, optic neuritis, congenital cataract, aniridia, achromatopsia, paediatric glaucoma, congenital 210 
stationary night blindness, chronic central serous retinopathy, and Leber’s congenital amaurosis.    211 
 212 
A. Efficacy 213 
Visual acuity (Table 1, Figure 3) was significantly different between conditions (F = 223.14, p < 214 
0.0001, ηp2 = 0.817). Post hoc analysis revealed a significant difference between baseline and normal 215 
mode (p < 0.0001) as well as baseline and preferred enhanced mode (p < 0.0001), but not between 216 
 
normal and enhanced mode (p = 0.292). Visual acuity improved by a mean (SD) of 0.63 (0.34) 217 
logMAR – more than 6 lines on the sight chart – to 0.20 (0.28) logMAR in normal mode (N = 58) and 218 
by 0.70 (0.32) logMAR – 7 lines – to 0.16 (0.26) logMAR in preferred enhanced mode (N = 51). Visual 219 
acuity improved in all but one participant, achieving 0.2 logMAR or better irrespective of baseline 220 
acuity in 67% of participants. 221 
 222 
Contrast sensitivity (Table 1, Figure 3) was significantly different between conditions (F = 52.45, p < 223 
0.0001, ηp2 = 0.527). Post hoc analysis revealed a significant difference between all pairwise 224 
comparisons (p < 0.0001). Contrast sensitivity improved by a mean (SD) of 0.22 (0.30) log units to 225 
1.21 (0.47) log units (6%) in normal mode (N = 55) and by 0.40 (0.31) log units to 1.37 (0.50) log units 226 
(4%) in preferred enhanced mode (N = 48).  227 
 228 
For reading performance (Table 1), near visual acuity (Figure 3) was significantly different between 229 
conditions (F = 6.07, p = 0.015, ηp2 = 0.155). Post hoc analysis revealed a borderline significant 230 
difference between baseline and normal (p = 0.051) and preferred enhanced mode (p = 0.049), but 231 
not between the two modes (p = 1.000). Near visual acuity improved by a mean (SD) of 0.15 (0.35) 232 
logMAR to 0.44 (0.32) logMAR – about font size 9 pt – in normal mode (N = 47) and by 0.16 (0.35) to 233 
0.46 (0.31) logMAR in preferred enhanced mode (N = 34). Critical print size was significantly different 234 
between conditions (F = 5.87, p = 0.005, ηp2 = 0.168). Post hoc analysis revealed a significant 235 
difference between baseline and normal (p = 0.043) and baseline and preferred enhanced mode (p = 236 
0.028), but not between the two modes (p = 1.000). Critical print size improved by a mean (SD) of 237 
0.22 (0.33) logMAR to 0.54 (0.33) – about font size 11 pt – in normal mode (N = 43) and by 0.21 238 
(0.34) logMAR to 0.55 (0.33) in preferred enhanced mode (N = 30). Peak reading speed was 239 
significantly different between conditions (F = 11.47, p < 0.0001, ηp2 = 0.283). Post hoc analysis 240 
revealed a significant difference between baseline and normal (p = 0.002) and preferred enhanced 241 
mode (p = 0.007), but not between the two modes (p = 0.604). Peak reading speed fell by a mean 242 
 
(SD) of 24.98 (30.55) words per minute to 56.02 (37.30) words per minute in normal mode (N = 43) 243 
and by 24.07 (34.16) words per minute to 62.23 (40.56) words per minute in preferred enhanced 244 
mode (N = 30). 245 
 246 
Table 1. Efficacy metrics. 247 
Outcomes for five efficacy metrics across the three study conditions. Conditions with the same 248 
superscript (a,b) were significantly different from each other in pairwise post-hoc tests (Bonferroni 249 
correction) following a repeated measures ANOVA. Not all participants completed all conditions: for 250 
example, some participants were unable to align the device for certain tests, and some participants 251 
were unable to read with it.  Where participants disliked all enhanced modes, assessment was not 252 
performed with the enhanced mode. 253 
 254 
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Figure 3. Mean (SE) distance visual acuity, contrast sensitivity and near visual acuity across the three 258 
study conditions. ‘Enhanced mode’ describes the preferred enhanced mode chosen by participants. 259 
 260 
B. Willingness to use ehLVA 261 
A total of 28 participants (47%) indicated that they would use an ehLVA like SightPlus, 27 262 
participants (45%) would not and 5 participants (8%) were not sure.  263 
 264 
Examined individually, seven variables had a significant effect on willingness to use an ehLVA like 265 
SightPlus (Table 2): age, affected proportion lifetime, baseline contrast sensitivity, difference in 266 
visual acuity with SightPlus (baseline vs. normal mode), history (acquired vs. inherited), use of e-LVAs 267 
including smartphones/tablets (yes / no) and work status (working / not working). 268 
Multivariate logistic regression resulted in a model with three variables: proportion of lifetime 269 
affected (Х2 = 6.4, p = 0.012), baseline contrast sensitivity (Х2 = 5.6, p = 0.018) and use of e-LVAs (Х2 = 270 
13.1, p < 0.001).  This model explained 41% of the observed variation (Cox and Snell pseudo R2 = 271 
0.405). 272 
 273 
Table 2. Willingness to use ehLVA vs. individual variables. 274 
Predictive power of individual variables for willingness to use an ehLVA like SightPlus. Outcomes of 275 
independent t-tests for continuous variables and Х2 tests for categorical variables. Effect size 276 
 
calculated as the mean difference between ‘yes’ and ‘no’ cohort. * significant effect with alpha = 277 
0.05. 278 
 Would you use an ehLVA like SightPlus?   











Age (years) 27 58 (20) 28 43 (16) 15 0.003* 
Time since diagnosis 
(years) 
27 15 (18) 28 23 (13) -7 0.082 
Proportion lifetime with 
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 Count A Count B Count A Count B   
Gender (male (A)/ female 
(B)) 
16 11 17 11  1.000 
History (inherited (A)/ 
acquired (B)) 
15 12 25 3  0.007* 
Progression (progressive 
(A)/ stable (B)) 
20 7 22 6  0.758 
Use of e-LVAs (yes (A)/ no 
(B)) 
5 22 20 8  <0.001* 
Work status (working (A)/ 
not working (B)) 
     0.015* 
Visual field status (central, 
full, mixed, peripheral)      
0.394 
 279 
C. Preferred mode 280 
 
A total of 35 participants (58%) preferred the ‘normal’ mode, ten (17%) preferred ‘inverted’, three 281 
(5%) preferred ‘contrast’, two preferred ‘enhanced’ and one preferred ‘text’.  The remaining seven 282 
participants reported that preference depended on the task. 283 
 284 
D. Qualitative analysis 285 
The 33 participants who indicated that they would use an ehLVA like SightPLus or that were not sure 286 
reported a total of 20 different activities as envisaged use cases: television (N=14), reading (N=7), 287 
theatre (N=6). reading with children (N=3), finding things (N=3), low light conditions (N=3), 288 
cinema/films (N=3), school/college (N=3), watching sports (N=2), signs (N=2), faces (N=2), computer 289 
(N=2), buses (N=1), board games (N=1), gardening (N=1), needle threading (N=1), seeing packets 290 
(N=1), form filling (N=1) and video games (N=1). 291 
 292 
The most commonly cited strengths of the device were the image clarity (N=10), the image 293 
brightness (N=6), the level of zoom (N=5) and its comfort (N=2).  294 
 295 
The most frequent criticism of the device was its weight (too heavy, N=26), aesthetic appearance 296 
(N=14), image movement or image lag (N=12), preference of own magnifiers (N=9) and not being 297 
able to walk with the device (N=6). Other reasons included occlusion of the far periphery through 298 
the headset (N=5), not finding it helpful (N=4) and disorientation or problems with depth perception 299 
(N=4). 300 
 301 
Adverse reactions 302 
Most of the participants did not report any adverse reaction (48 of 60 participants, 80%). Twelve 303 
participants (20%) reported a single adverse reaction and none reported multiple adverse reactions. 304 
The most frequently reported adverse reactions were nausea (N=4, 7%) and dizziness (N=4, 7%). 305 
Three participants experienced a headache with the device and one participant (with a documented 306 
 
history of dry eye) described “sore eyes”.  No participants reported claustrophobia or eye strain. In 307 
all cases, symptoms resolved on removal of the headset while participants were in clinic. For six 308 
participants (three with nausea, and one with each of headache, sore eyes and dizziness), reactions 309 
were severe enough for the investigator to terminate the study session early. Data for these 310 
participants until the point of termination were analysed. 311 
 312 
Discussion 313 
  314 
Summary of findings 315 
This study investigated improvements in vision and the willingness to use an ehLVA using SightPlus 316 
(GiveVision, UK). SightPlus provided clinically significant and functionally relevant improvements in 317 
visual acuity and contrast sensitivity: distance visual acuity improved by more than 6 lines on a 318 
logMAR chart, and contrast sensitivity improved by 8 letters with image enhancement. Half of our 319 
study population indicated willingness to use the device. Examining predictor variables individually, 320 
we found a significant effect for willingness to use an ehLVA for those with younger age, longer 321 
proportion of lifetime with visual impairment, lower baseline contrast sensitivity, greater 322 
improvement in visual acuity with SightPlus (baseline vs. normal mode), inherited sight loss 323 
(compared to acquired sight loss), existing use of electronic LVAs (including smartphones/tablets) 324 
and working. Multivariate logistic regression reduced this parameter space to the proportion of 325 
lifetime affected, baseline contrast sensitivity and use of electronic LVAs, explaining 41% of the 326 
variation in the data. This illustrates that while the examined factors may predict the likelihood of 327 
uptake to a degree, factors beyond the scope of this study also play a role. While we anticipated that 328 
current use of electronic LVAs would predict willingness to use, we were surprised to find that 329 
baseline acuity was not a predictor. This shows that lifestyle and other factors maybe more 330 




Improvements in performance on standard sight tests were similar to those reported for the eSight 334 
ehLVA device, which gave a mean (SD) of 0.20 (0.31) logMAR (compared to 0.20 (0.28) logMAR in 335 
the present study) and contrast sensitivity of 1.44 (0.44) log units (compared to 1.21 (0.47) log units 336 
in normal mode and 1.37 (0.50) log units with preferred enhanced mode in the present study).17  337 
While participants in the eSight trial were self-selected through wanting to use eSight, participants in 338 
the present study were a random sample from a low vision clinic. Given the similarity between our 339 
results and the eSight study, a prior disposition of wanting to use an ehLVA is unlikely to predict 340 
efficacy. 341 
 342 
For reading performance, we found a smaller positive effect compared to eSight:17 near visual acuity 343 
and critical print size improved significantly with SightPlus, albeit to a smaller degree (near visual 344 
acuity improved from 0.90 to 0.33 logMAR with eSight and 0.56 to 0.44 logMAR with SightPlus; 345 
critical print size improved from 1.08 to 0.59 logMAR for eSight and 0.75 to 0.54 logMAR with 346 
SightPlus). While in the eSight study there was no significant effect of the ehLVA on reading speed,17 347 
we detected a significant decrease in reading speed with SightPlus (from 79 to 56 words per minute 348 
in normal mode and to 62 words per minute in preferred enhanced mode). A reduction in reading 349 
speed could be explained by reduced visual span, or by image movement. A 2018 review of studies 350 
evaluating reading aids for people with low vision found that reading speed may be highest in stand-351 
mounted electronic CCTVs compared to optical devices, with further evidence for longer reading 352 
durations and better ease of use.22 Comparing stand-mounted CCTV and head-mounted devices 353 
(HMDs), the review reported similar performance between the two: for  HMDs, on average 66 words 354 
per minute and near visual acuity of 0.92 logMAR; for CCTVs, 3.1 words per minute more for reading 355 
speed and 0.05 logMAR more for near visual acuity. It is important to note that near visual acuity for 356 
the ehLVAs reported here substantially exceeded those outcomes. Despite the reduced speed in our 357 
study, several participants indicated that they would choose to use SightPlus for reading, perhaps 358 
 
because of the increased working distance, comprehension or comfort of reading, none of which we 359 
assessed. 360 
 361 
Willingness to use 362 
Half of our study population indicated that they were willing to use an ehLVA like SightPlus, 363 
especially for activities such as television, reading or theatre, with many individual activities named. 364 
Similarly, a recent large-scale review into functional sight in AMD reported that face recognition, 365 
perception of scenes, computer use, meal preparation, shopping, cleaning, watching TV, reading and 366 
self-care are among the tasks negatively affected by sight loss.23 Future ehLVAs should aim to 367 
support such common activities to enable independence and improvement in quality of life.  368 
 369 
Seven individual variables predicted a higher willingness to use an ehLVA like SightPlus. Our results 370 
agree with the literature summarised in a recent review:24 for example, younger age has been found 371 
to be a predictor of better compliance; duration of vision loss may predict greater uptake (similar to 372 
our ‘proportion of lifetime affected’ predictor).  In our study, as in most previous work, there was no 373 
effect of baseline acuity on uptake or benefit. Our univariate and multivariate analysis showed that 374 
existing use of electronic devices was a strong predictor for willingness to use an ehLVA like 375 
SightPlus. It is not clear whether comfort with technology was a significant factor in this. The role of 376 
technological literacy should be explored in future studies, especially for older people. Proportion of 377 
lifetime affected and baseline contrast sensitivity also had an effect in this model. Those diagnosed 378 
for proportionally longer may have adapted more to their sight loss and be more willing to seek 379 
assistance,25 although this requires further research.  380 
  381 
The most common reasons for not wanting to use the device were its weight, 465g (26 of 60 382 
participants), its appearance (14 of 60 participants) and perceived image movement or image lag (12 383 
of 60 participants). Weight and appearance are inherent to virtual reality (VR) headset-based 384 
 
solutions like SightPlus or IRIS Vision, although can be overcome through bespoke designs such as 385 
that pioneered by eSight. In future, creating lighter and more comfortable to wear devices will be an 386 
important design consideration. Perceived image movement and image lag can arise from head 387 
movement, throttled processing speed or optical image stabilisation resulting in slight lag of the 388 
scene relative to head movement. Improved image stabilisation, zero-lag image processing and 389 
compensation for fast changes in head orientation could all make this effect less noticeable.   390 
 391 
Exactly half of those who met the World Health Organisation criterion for low vision (visual acuity 392 
poorer than 6/18) would use a ehLVA like SightPlus, compared to 47% of our complete sample. We 393 
could not determine the lower acuity limit for SightPlus to be useful: the participant with the 394 
poorest visual acuity (perception of light in the right eye, hand movements in the left eye) improved 395 
to 0.06 logMAR (6/7; 20/23) and would use the device for work and television. 396 
   397 
Outlook 398 
As more wearable low vision devices become available, a standardised test battery or unified task 399 
inventory of real-life activities would enable true comparison of different devices and quantify their 400 
impact on performance of common daily tasks. No such comparison has yet been performed, and 401 
limited data are available on new wearable devices.2 Assessment of visual function beyond acuity 402 
and contrast sensitivity has been called for in a large-scale review of visual function and quality of 403 
life in AMD23 and would enable comprehensive evaluation and benchmarking of all types of low 404 
vision aids.  A comparative study of devices would be invaluable to clinicians, patients and carers.  405 
Our clinical experience with this device suggests that existing inventories may need to be revised to 406 
reflect common, modern real-world tasks across a broad age group. Any such evaluation package 407 
should contain tasks most commonly needing visual aids by people with low vision while being 408 
repeatable across different institutions. Examples of this include the inclusion of face recognition by 409 
Wittich17 and a bespoke (albeit unvalidated) task inventory used by Orcam.18  Future work should 410 
 
expand on this to include measurable performance, avoiding the confounding effects of self-411 
reporting and observation.  The impact of ehLVAs on quality of life needs to be established in order 412 
to facilitate any future health economic assessments. 413 
 414 
Study limitations 415 
Our inclusion criteria were deliberately broad in order to determine who would most benefit from 416 
this system.  Since we did not find clear cut-offs with regards to minimum or maximum baseline 417 
visual acuity for those who benefit from an ehLVA, future work should either use a stratified 418 
sampling method with a larger sample size, or focus on specific disease conditions to identify patient 419 
beneficiaries more robustly. Visual acuity may not be a predictor of benefit or uptake, and future 420 
work should continue to examine a broad range of predictor variables. 421 
 422 
In this study, we allowed participants free choice of the image enhancement mode which they found 423 
most useful for a given task. Our results for ‘preferred enhanced mode’ hence contain different 424 
modes.   Although visual acuity and contrast sensitivity improved further with image enhancement 425 
as well as zoom, 58% of participants preferred the ‘normal’ mode. It is important to note that the 426 
outcomes we used were letter and text based. Enhancement mode preferences for images 427 
containing a broader range of colours and spatial frequencies (such as natural scenes or TV) may  428 
differ. Previous research has shown that participants tend to prefer the most natural looking image 429 
rendering through lower level enhancements, and that preferences depend on the nature of sight 430 
loss and image content.16 26  Further work is needed to link image enhancement modes to tasks and 431 
sight loss conditions, as has been attempted by other groups.12 13 432 
 433 
Adverse reactions were reported by 12 participants (20%), with nausea and dizziness being the most 434 
common unpleasant sensations.  Nausea has been reported as a side-effect of wearable devices.8 17 435 
These symptoms resolved as soon as the device was removed. Six participants (10%) were not able 436 
 
to complete the full study session due to adverse effects.  Future work should investigate the causes 437 
of these adverse effects and should endeavour to remove them by, for example, providing a less 438 
enclosed design. 439 
 440 
Conclusions 441 
This augmented reality low vision aid improves visual acuity, contrast sensitivity and near visual 442 
acuity. Approximately half of the people we demonstrated it to would want to use it, primarily for 443 
distance tasks. Uptake of the device would be higher if it was lighter and more cosmetically 444 
acceptable. We recommend that adults with low vision are given the opportunity to evaluate ehLVAs 445 
until larger scale studies can help better characterise those for whom these devices will prove 446 
particularly beneficial.  447 
 448 
The efficacy of ehLVAs has now been demonstrated in two devices with different form factor and 449 
display technology (eSight and SightPlus).  Research now needs to move beyond the clinic, to 450 
quantify the benefits of these systems for visually impaired people at work, in education, and at 451 
home.  We hope that electronic, head-mounted low vision aids become more widely used and that 452 
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